PDF(Pubmed)
Abstract：
The effect of high-dose pyridoxine (PN) on activity of 5-fluorouracil (FUra) and folinic acid (FA)-containing regimens was studied in 50 patients including 14 with digestive tract, and 36 with breast carcinomas (BC) in advanced stages with poor prognostic characteristics. Patients with colorectal, and pancreas adenocarcinoma received oxaliplatin, irinotecan, FUra, FA (Folfirinox), and patients with squamous cell carcinoma of the esophagus had paclitaxel, carboplatin, FUra, FA (TCbF). Patients with BC received AVCF (doxorubicin, vinorelbine, cyclophosphamide, FUra, FA) followed by TCbF or TCbF only, and patients who overexpressed HER2 received TCbF plus trastuzumab and pertuzumab. PN (1000-3000 mg/day iv) preceded each administration of FUra and FA. 47 patients (94%) responded, including 16 (32%) with CR. Median tumor reduction was 93%. Median event-free survival (EFS) was 37.7 months. The 25 patients with tumor shrinkage ≥ 91% had EFS of 52% from 42 months onwards. Unexpected toxicity did not occur. PN enhances potency of chemotherapy regimens comprising FUra and FA.
摘要：
在50例患者中研究了大剂量吡哆醇（PN）对含5-氟尿嘧啶（FUra）和亚叶酸（FA）的活性的影响，其中包括14例消化道患者，和36例晚期乳腺癌（BC），预后特征较差。结直肠患者，胰腺腺癌接受奥沙利铂，伊立替康,FUra,FA(Folfirinox)，食管鳞状细胞癌患者接受紫杉醇治疗，卡铂,FUra,FA(TCbF)。BC患者接受了AVCF（阿霉素，长春瑞滨,环磷酰胺,FUra,FA)其次是TCbF或TCbF，过表达HER2的患者接受TCbF+曲妥珠单抗和帕妥珠单抗治疗.PN(1000-3000mg/天iv)先于FUra和FA的每次给药。47名患者（94%）有反应，包括16个（32%）CR。中位肿瘤减少为93%。中位无事件生存期（EFS）为37.7个月。肿瘤收缩≥91%的25例患者从42个月开始的EFS为52%。未发生意外毒性。PN增强包含FUra和FA的化疗方案的效力。
